mze829
·Code: MZE829
mze829: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Maze Therapeutics, Inc. (MAZE) | Phase 2 |
Clinical Trials (1)
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Frequently asked questions
Who is developing mze829?
mze829 is being developed by Maze Therapeutics, Inc..
How many clinical trials involve mze829?
BioSniper tracks 1 clinical trial involving mze829.
Get deeper analysis on mze829
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis